UnJungKangMD

PubMed

• Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis.
  Lorraine V Kalia, Angelica Asis, Nathalie Arbour, Amit Bar-Or, Riley Bove
  Nature Reviews. Neurology. 2024-12-01
• 2 citations
  Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study.
  Yihua Ma, Carly M Farris, Sandrina Weber, Sebastian Schade, Hieu Nguyen
  The Lancet. Neurology. 2024-12-01
• Neuron-derived extracellular vesicles to examine brain mTOR target engagement with sirolimus in patients with multiple system atrophy.
  Krishna A Pucha, Thong C Ma, William York, Un Jung Kang, Horacio Kaufmann
  Parkinsonism & Related Disorders. 2023-10-01

Journal Articles

• Axctosidase A activity in Parkinson�s disease  
  Alcalay RN, Wolf P, Levy OA, Kang UJ, Waters C, Fahn S, Ford B, Kuo SH, Vanegas N, Shah H, Liong C, Narayan S, Pauciulo MW, Nichols WC, Gan-Or Z, Rouleau GA, Chung WK..., Neurobiology of Disease; Neurobiol Dis, 1/1/2018
• Enhanced histamine H2 excitation of striatal cholinergic interneurons in L-DOPA-induced dyskinesia  
  Lim A, Xia R, Ding Y, Won L, Ray WJ, Hitchcock SA, McGehee D, Neurobiol Dis, 1/1/2015
• Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial  
  Jennings D, Eberly S, Oakes D, Seibyl J, Marek K, Shoulson I; Parkinson Study Group PRECEPT Investigators, J Parkinsons Dis, 1/1/2014
• Longitudinal follow-up of SWEDD Subjects in PRECEPT study  
  Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang A, Hyson C, Jennings D, and The Parkinson Study Group PRECEPT Investigators, Neurology, 1/1/2014
• The role of DaScan and clinical diagnosis in PD  
  Xie T, Warnke P, Kang UJ, Write Click Neurology, 1/16/2012
• CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion  
  Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, A..., Neurology, 1/6/2012
• Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2  
  Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER,..., Ann Neurol, 1/1/2012
• Characterization of a Large Group of Individuals with Huntington Disease and Their Relatives Enrolled in the COHORT Study  
  Dorsey ER, the Huntington Study Group COHORT Investigators, PloS ONE, 1/1/2012
• Serum urate and probability of dopaminergic deficit in early "Parkinson's disease"  
  Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A; Parkinson Study Group PRECEPT Investigators, Mov Disord, 1/15/2011
• Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN�, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia  
  Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S; U.S. XEOMIN Cervical Dystonia Study Group, J Neurol Sci, 1/15/2011
• Copy number variation in familial Parkinson disease  
  Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, Halter C, Doheny KF, Gusella JF, Nichols WC, Myers RH, Foroud T, DeStefano AL; PSG-PROGENI and GeneP..., PLoS One, 1/1/2011
• Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts  
  Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE; Parkinson Study Group DATATOP and PRECEPT investigators, Mov Disord, 1/1/2011
• Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease  
  Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators, Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kiebu..., Mov Disor, 1/15/2010
• Genome-wide association study for onset age in Parkinson disease  
  Latourelle JC, Pankratz N, Dumitriu A, Wilk JB, Goldwurm S, Pezzoli G, Mariani CB, DeStefano AL, Halter C, Gusella JF, Nichols WC, Myers RH, Foroud T; PROGENI Investig..., BMC Med Genet, 1/22/2009
• A Longitudinal Program for Biomarker Development in Parkinson disease: a Feasibility Study  
  Ravina B, Tanner C, DiEuliis D, Eberly S, Flagg E, Galpern WR, FahnS , Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I, and ..., Mov Disord, 1/18/2009
• A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts  
  Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I; Parkinson Study Group DATATOP and PRECEPT investigators, Mov Disord, 1/15/2009
• Serum urate as a predictor of clinical and radiographic progression in Parkinson disease  
  Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A; Parkinson Study Group PRECEPT Investigators, Hyson C, Gorbold E, Rudolph A, Ki..., Arch Neurol, 1/1/2008
• Clinical correlates of depressive symptoms in familial Parkinson�s disease  
  Pankratz N, Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, Foroud T, Parkinson�s Study Group � PROGENI Investigators, Mov Disord, 1/1/2008
• The mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson�s Disease  
  The Parkinson Study Group PRECEPT Investigators, Neurology, 1/1/2007
• Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms  
  Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, Oakes D, Blindauer K, Salzman P, Oren S, Prisco UL, Stern M, Shoulson I, the Parkinson Study Group TEMPO and ..., J Neurol Sci, 1/6/2006
• Safety of rasagiline in elderly Parkinson�s disease patients  
  Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I, the Parkinson Study Group TEMPO and PRESTO Investigators, Neurology, 1/1/2006
• Mutations in LRRK2 other than G2019S are rare in a North American�based sample of familial Parkinson�s Disease  
  Pankratz N, Pauciulo M, Elsaesser V, Marek D, Halter C, Rudolph A, Shults C, Foroud T, Nichols W, the Parkinson Study Group - PROGENI Investigators, Movement Disorders, 1/1/2006
• Mutations in DJ-1 are rare in familial Parkinson disease  
  Pankratz N, Pauciulo M, Elsaesser V, Marekb D, Halter C, Wojcieszek J, Rudolph A, Shults C, Foroud T, Nichols W, the Parkinson Study Group - PROGENI Investigators, Neuroscience Letters, 1/1/2006
• A Controlled, randomized, delayed-start study of rasagiline in early Parkinson Disease  
  Parkinson Study Group, Arch Neurol, 1/1/2004
• Rating scales for dystonia a multi-center assessment  
  Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T, the Dystonia Study Group, Mov Disord, 1/1/2003
• Join now to see all

Books/Book Chapters

• Merritt�s Neurology 
  Chapter: Chapter 80. Tardive dyskinesia 
  Kang UJ, Burke RE, Fahn SEditors: Louis ED, Mayer SA, Rowland LP.Wolters KluwerEdition 13th,2015
• Merritt�s Neurology 
  Chapter: Chapter 83. Parkinson�s disease 
  Fahn S, Kang UJEditors: Louis ED, Mayer SA, Rowland LP.Wolters KluwerEdition 13th,2015
• Parkinson�s Disease 
  Chapter: Chapter 53. Clinical Batteries and Biomarkers in the Diagnosis of Parkinson�s Disease 
  Henchcliff C, Kang UJEditors: Pfeiffer RF, Ebadi M, Wxzolek Z.CRC PressEdition 2nd,2013
• Encyclopedia of Neuroscience 
  Chapter: Gene Therapy: genetically modified cells 
  Kang UJEditors: Squire LR.Oxford: Academic Press2009
• Textbook of Neural Repair and Neurorehabilitation 
  Chapter: Neurotrophic Factor Delivery by Gene Therapy 
  Nakamura K, Kang UJEditors: Selzer ME, Cohen L, Gage FH, Clarke S, Duncan PW.Cambridge University Press2005
• Surgical Treatment of Parkinson�s Disease and other Movement Disorders 
  Chapter: Future Surgical Therapies in Parkinson�s Disease 
  Kang UJ, Chang J, Lee W, Papasian NEditors: Tarsy D, Vitek JL, Lozano AM.Humana Press, Totowa, NJ2002
• Principles of Surgery for Parkinson�s Disease and Movement Disorders 
  Chapter: The potentials of gene therapy for treatment of Parkinson�s Disease 
  Kang UJ, Isacson OEditors: Krauss JK, Jankovic J, Grossman RG.Lippincott, Williams & Wilkins, Philadelphia2001
• Dystonia 3. Advances in Neurology 
  Chapter: The effect of GTP cyclohydrolase I on tyrosine hydroxylase expression: implications in DOPA-responsive dystonia 
  Kang UJ, Bencsics C, Wachtel S, Lew REditors: Fahn S, Marsden CD, DeLong M.Lippincott-Raven Publishers, Philadelphia1998
• Viral Vectors: Gene Therapy and Neuroscience Applications 
  Chapter: Genetic modification of cells with retrovirus vectors for grafting into the central nervous system 
  Kang UJEditors: Kaplitt MG, Loewy AD.Academic Press, San Diego1995
• Merritt's Text Book of Neurology 
  Chapter: Tardive dyskinesia 
  Kang UJ, Fahn SEditors: Rowland LP.Edition 8th,1989
• Dystonia 2. Advances in Neurology 
  Chapter: Natural history and treatment of tardive dystonia 
  Kang UJ, Burke RE, Fahn SEditors: Fahn S, Marsden CD, Calne DB.Raven Press, New York1988
• Facial dyskinesias advances in Neurology 
  Chapter: Tardive dystonia: clinical aspects and treatment 
  Burke RE, Kang UJEditors: Jankovic J, Tolosa E.Raven Press, New York1988
• Join now to see all

Abstracts/Posters

• Associative learning contributes to motor impairment after dopamine depletion and is associated with activation of striatopallidal spiny projection neurons
  Cheung T, Ding Y, Kang UJ, Gordon Conference on Basal Ganglia, 1/1/2018
• Modulating SNr neuronal activity in PD and LID
  Hu Y, Ma T, Ding Y, Kang UJ, Gordon Conference on Basal Ganglia, 1/1/2018
• A Prospective Clinical Cohort and Biorepository of Multiple System Atrophy (MSA)
  Kim J, Gupta D, Liong C, Ma T, Kang UJ, Kuo S-H, Alcalay R, Sklerov M, American Academy of Neurology Annual Meeting, Los Angeles, CA, 1/1/2018
• Parkinson's disease disrupts motor skill learning that requires improvement of a speed-accuracy trade-off
  Kim CY,�Zimnik A, Kang UJ, Mazzoni P, The MDS 21th International Congress of Parkinson�s Disease and Movement Disorders, Vancouver, BC, 1/1/2017
• Motor phenotype classification in moderate to advanced PD: data from the BioFIND study
  Luo L, Andrews HF, Goldman JG, Alcalay RN, Xie T, Tuite P, Henchcliffe C, Hogarth P, Amara A, Frank S, Rudolph A, Casaceli C, Gwinn K, Sutherland M, Kopil C, Vincent L..., The MDS 20th International Congress of Parkinson�s Disease and Movement Disorders, 1/19/2016
• L-DOPA-induced dyskinesia is associated with enhanced H2 histamine excitation of striatal cholinergic interneurons
  S. A. Lim, R. Xia, L. Won, Y. Ding, D. S. McGehee, U. J. Kang, Society for Neuroscience, San Diego, CA, 1/1/2013
• Deep brain stimulation in a case of hemichoreoathetosis with dystonia associated with a developmental venous anomaly and microbleeding in the subthalamic nucleus area
  Xie T, Awad I, Kang U, Warnke P, MDS meeting, 1/1/2013
• The role of M1 muscarinic receptors in L-DOPA induced dyskinesia
  Won, L. Ding, Y. Kang, U, Neuroscience Meeting Planner, New Orleans, LA, 1/1/2012
• Striatal cholinergic ERK activation associated with L-DOPA induced dyskinesia requires D1 receptor activation
  Ding, Y. Won, L. Kang, U, Neuroscience Meeting Planner, New Orleans, LA, 1/1/2012
• Activity and dopaminergic medication synergistically produce long lasting motor learning in Parkinson�s disease
  Kang UJ, Auinger P, Parkinson Study Group, Neuroscience Meeting Planner, Washington, DC, 1/1/2011
• The role of D5 dopamine receptors in striatal cholinergic activity associated with L-DOPA induced dyskinesia
  Won, L. Ding, Y. Campioni, M.R. Lim, S.A.O. MeGehee D.S. Kang, U, Neuroscience Meeting Planner, Washington, DC, 1/1/2011
• Loss of PINK1 decelerates glutamate-induced mitochondrial fission in mouse primary cortical neurons
  Lin, W. Chen, L.White, D. Won, L. Zhuang, X. Kang, U, Neuroscience Meeting Planner, San Diego, CA, 1/1/2010
• DJ-1 is axonal transported and secreted in mouse brains
  Xie Z, Chen L, Cheng H, Ding Y, Won L, Kang UJ , Zhuang X, Neuroscience Meeting Planner, Chicago. IL, 1/1/2009
• Inhibition of dopamine metabolism blocks neurodegeneration in a cytosolic dopamine toxicity mouse model
  Chen L, Xie Z, Ding Y, Won L, Hastings TG, Youdim MBH, Kang UJ , Zhuang X, Neuroscience Meeting Planner, Chicago. IL, 1/1/2009
• PINK1 kinase domain is involved in stability and not localizationProgram No. 545.17.
  Lin W, Simone AJ, Kang UJ, Society for Neuroscience, Washington, DC, 1/1/2008
• Chronic 3, 4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's Disease
  Ding Y, Restrepo J, Won L, Hwang D-Y, Kim K-S, Kang UJ., Society for Neuroscience, 1/1/2007
• P INK1 processing occurs in the mitochondria but localizes and degrades in the cytosol
  Lin W, Kang UJ, Society for Neuroscience, 1/1/2007
• Dysregulation of AChE splicing in acute and chronic models of Parkinson�s disease
  Potashkin J, Loomis P, Ding Y, Jodelka F, Jackolin J, Kang UJ and Meredith G., Society for Neuroscience, 1/1/2007
• Endogenous dopamine causes neurodegeneration in mice
  Chen L, Ding Y, Cagniard B, Chi W, Tian N, Vanlaar AD, Mortimer A, Hastings TG, Kang UJ, Zhuang X, 11th International Congress of Parkinson�s Disease and Movement Disorders, 1/1/2007
• Ubiquitin-proteasome system dysfunction and skeletal muscle atrophy in DJ-1-deficient mice 675.16/MM31)
  Chi W, Chen L, Yang W, Sun X, Kang UJ, Zhuang X, Society for Neuroscience, Washington, DC, 1/1/2006
• Endogenous dopamine causes neurodegeneration in mice (675.15/MM30)
  Chen L, Ding Y, Cagniard B, Chi W, Tian N, Vanlaar AD, Mortimer A, Hastings TG, Kang, UJ, Zhuang X, Society for Neuroscience, Washington, DC, 1/1/2006
• Loss of both DJ-1 and PINK1 leads to early embryonic lethality in mice (675.14/MM29)
  Zhuang X, Chi W, Fleming S, Ding Y, Kang UJ, Chen L, Society for Neuroscience, Washington, DC, 1/1/2006
• Redox-dependent molecular modification and activation of chaperone function of DJ-1 Program No. 1006.17
  Tian NS, Krencik R, Ding Y, Chen L, Zhuang X, Kang UJ, Society for Neuroscience, Washington, DC, 1/1/2005
• Identification and treatment of cervical and oromandibular dystonia in acutely brain-injured patients: a pilot study using botulinum toxin
  Lo SE, Rosengart AJ, Novakovic RL, Kang UJ, Dalvi A, Frank JI., 9th International Congress of Parkinson�s Disease and Movement Disorders, 1/1/2005
• Chronic delivery of muscimol into the subthalamic nucleus attenuates l-dopa-induced dyskinesia and improves akinesia in hemi-parkinsonian rats Program No. 88.13.
  Ding Y, Rokosik SL, Koh HC, Wright DA, Penn R, Kang UJ, Society for Neuroscience, Washington, DC, 1/1/2005
• Join now to see all

Lectures

• Aberrant motor learning in PD: learning to move slow? 
  1/30/2018
• Beyond dopamine and DBS in PD therapy: cell-type specific modulation 
  Florence, Italy - 1/14/2018
• Shaking it up 
  HNA Palisades Conference Center, Palisades, NY - 1/8/2018
• Aberrant and beneficial plasticity in PD 
  New York, NY - 1/3/2018
• Basal ganglia plasticity in Parkinson�s disease 
  Boston, MA - 1/20/2017
• Biomarkers for Parkinson�s disease: promises and pitfalls 
  State University of New York, Brooklyn, NY - 1/17/2017
• Cholinergic cells in dyskinesia: Experimental evidence and novel treatments 
  Portland OR - 1/23/2016
• Clinical features of dyskinesia: what, when, and why 
  Portland, OR - 1/22/2016
• Dyskinesia � An ever moving story 
  Portland OR - 1/22/2016
• Basal Ganglia Plasticity in PD Therapy: the good and the bad 
  Columbia University, 2013; Columbia University, 2014 - 1/1/2014
• Adaptive Mechanisms underlying the Short- and Long-Duration Response 
  1/23/2012
• Animal models: what have they taught us about PD? 
  1/19/2011
• Parkinson�s Disease: Practical management issues 
  University of Chicago, Chicago, IL - 1/20/2010
• The molecular mechanisms of beneficial and aberrant plasticity in PD therapy 
  Seoul, Korea - 1/17/2010
• Mechanisms of Parkinson�s Disease Genes 
  Pusan, Korea - 1/1/2009
• Lessons on Pathogenesis of Parkinson�s Disease from Genetic Studies: Oxidative Stress and DJ-1 
  Albert Einstein College of Medicine, New York, NY - 1/20/2008
• Pathophysiological Insights from Recessive Forms of PD 
  Yonsei University, Seoul, Korea - 1/20/2008
• Gene Therapy for Pediatric Neurotransmitter Diseases 
  Washington, D.C. - 1/17/2008
• Parkinon�s Disease 
  Daejeon, Korea - 1/14/2008
• The role of PINK1 in Parkinson�s Disease 
  San Diego - 1/1/2008
• 50 Years of Dopamine in Parkinson�s Disease: a Time to Retire? 
  1/23/2007
• The Promise and Pitfalls of Biomarkers for Diagnosis and Evaluation of Parkinson�s Disease 
  Brown University School of Medicine, Providence, RI - 1/21/2007
• Diagnosis of Parkinson's Disease: Clinical Pearl in Need of Biomarkers 
  University of Chicago, Chicago, IL - 1/20/2007
• Pathophysiology of Parkinson�s Disease: Insights from Genetic Models 
  Northwestern University, Chicago, IL - 1/13/2007
• The genetic Mouse Models of Parkinson�s Disease 
  Korean Advanced Institute of Science and Technology, Daejeon, Korea - 1/3/2007
• Join now to see all